Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Will Look At Risk Communications In Two Separate Assessments

This article was originally published in The Pink Sheet Daily

Executive Summary

Two studies are planned for 2006 to find out more about healthcare professionals' preferences for learning about medical risks.

You may also be interested in...

Industry Proposes Retiring The Term “Recall,” But FDA Has Concerns

Medtronic VP Susan Alpert suggests renaming recalls "field safety corrective actions" in accordance with a recent Global Harmonization Task Force proposal. The issue was debated at an FDA/AdvaMed post-market workshop Feb. 9.

TyRx Says Combination Products Offer Greater Opportunity Than Drug Delivery

The firm takes its first step toward launching an anesthetic surgical mesh product after shifting its focus from drug delivery to combination products.

FDA Panel Suggests Zero Tolerance For Blood Deposits On Jet Injectors

Felton International and PATH present disposable protector cap as a solution to cross contamination at the General Hospital and Personal Use Devices Panel meeting Aug. 9.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts